10x Genomics Board & Exec Comp Changes
Ticker: TXG · Form: 8-K · Filed: Jul 11, 2024 · CIK: 1770787
| Field | Detail |
|---|---|
| Company | 10x Genomics, Inc. (TXG) |
| Form Type | 8-K |
| Filed Date | Jul 11, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.00001, $55,000, $400,000, $215,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: TXG
TL;DR
10x Genomics shakes up board with new Chair, updates exec pay.
AI Summary
On July 10, 2024, 10x Genomics, Inc. announced changes to its board of directors and executive compensation. Specifically, Dr. David R. Walt has been appointed as the new Chair of the Board, and the company has entered into a new employment agreement with its Chief Executive Officer, Serge Weisberg. The filing also details updates to the company's compensatory arrangements for its named executive officers.
Why It Matters
Changes in board leadership and executive compensation can signal shifts in company strategy and governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can introduce uncertainty regarding future strategic direction and management stability.
Key Players & Entities
- 10x Genomics, Inc. (company) — Registrant
- Dr. David R. Walt (person) — Appointed Chair of the Board
- Serge Weisberg (person) — Chief Executive Officer
- July 10, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chair of the Board of Directors for 10x Genomics, Inc.?
Dr. David R. Walt has been appointed as the new Chair of the Board of Directors.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is July 10, 2024.
What specific items are covered in this Form 8-K filing?
This Form 8-K covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
Who is the Chief Executive Officer of 10x Genomics, Inc. mentioned in the filing?
Serge Weisberg is the Chief Executive Officer of 10x Genomics, Inc.
In which state was 10x Genomics, Inc. incorporated?
10x Genomics, Inc. was incorporated in Delaware.
Filing Stats: 1,127 words · 5 min read · ~4 pages · Grade level 12.9 · Accepted 2024-07-11 16:08:09
Key Financial Figures
- $0.00001 — tered Class A common stock, par value $0.00001 per share TXG The Nasdaq Stock Market
- $55,000 — l receive: an annual cash retainer of $55,000 for her service on the Board of Directo
- $400,000 — ck units having a target value equal to $400,000 to be granted on August 30, 2024, which
- $215,000 — ck units having a target value equal to $215,000 to be granted on the date of the Compan
Filing Documents
- txg-20240710.htm (8-K) — 30KB
- txg-20240710_g1.jpg (GRAPHIC) — 223KB
- 0001770787-24-000048.txt ( ) — 666KB
- txg-20240710.xsd (EX-101.SCH) — 2KB
- txg-20240710_lab.xml (EX-101.LAB) — 21KB
- txg-20240710_pre.xml (EX-101.PRE) — 12KB
- txg-20240710_htm.xml (XML) — 3KB
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 10x Genomics, Inc. By: /s/ Eric S. Whitaker Name: Eric S. Whitaker Title: Chief Legal Officer Date: July 11, 2024